Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,316 | 314 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,617 | 96 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $816.83 | 40 | $0 (2024) |
| Janssen Biotech, Inc. | $463.09 | 21 | $0 (2024) |
| QOL Medical, LLC | $434.64 | 14 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $259.38 | 14 | $0 (2024) |
| PFIZER INC. | $205.80 | 11 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $202.01 | 10 | $0 (2024) |
| Lilly USA, LLC | $188.50 | 6 | $0 (2024) |
| Celgene Corporation | $184.54 | 7 | $0 (2024) |
| GENZYME CORPORATION | $166.87 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,868 | 82 | ABBVIE INC. ($571.40) |
| 2023 | $1,046 | 45 | AbbVie Inc. ($246.46) |
| 2022 | $255.90 | 9 | GENZYME CORPORATION ($104.60) |
| 2021 | $11.62 | 1 | AbbVie Inc. ($11.62) |
| 2020 | $472.90 | 25 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($99.30) |
| 2019 | $853.81 | 45 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($202.07) |
| 2018 | $858.82 | 53 | AbbVie, Inc. ($216.37) |
| 2017 | $949.30 | 54 | AbbVie, Inc. ($266.61) |
All Payment Transactions
314 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: Gastroenterology | ||||||
| 12/19/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $41.23 | General |
| Category: THERAPY FOR CSID | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.06 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: Gastroenterology | ||||||
| 12/03/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $11.66 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Immunology | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: Gastroenterology | ||||||
| 11/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.75 | General |
| 10/24/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Gastroenterology | ||||||
| 10/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $11.17 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $28.52 | General |
| Category: Immunology | ||||||
| 10/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $28.96 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/07/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $43.08 | General |
| Category: THERAPY FOR CSID | ||||||
| 10/03/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $3.29 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/02/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.07 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Gastroenterology | ||||||
| 09/24/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $11.90 | General |
| Category: IMMUNOLOGY | ||||||
| 09/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $4.69 | General |
| Category: IMMUNOLOGY | ||||||
| 09/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 638 | 687 | $382,028 | $72,327 |
| 2022 | 18 | 919 | 1,000 | $566,678 | $115,514 |
| 2021 | 17 | 933 | 1,107 | $536,701 | $112,892 |
| 2020 | 17 | 909 | 1,025 | $419,165 | $84,114 |
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 125 | 126 | $135,450 | $25,657 | 18.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 113 | 132 | $44,653 | $12,532 | 28.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 152 | 173 | $40,005 | $11,415 | 28.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 67 | 69 | $48,645 | $6,189 | 12.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 52 | 53 | $50,880 | $4,773 | 9.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $13,440 | $3,271 | 24.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 15 | 15 | $12,075 | $2,752 | 22.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 27 | 27 | $9,045 | $2,611 | 28.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $3,700 | $1,027 | 27.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 15 | $2,925 | $953.55 | 32.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $8,400 | $931.01 | 11.1% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Facility | 2023 | 11 | 12 | $11,640 | $157.52 | 1.4% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 13 | 13 | $1,170 | $56.99 | 4.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 148 | 149 | $160,175 | $30,208 | 18.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 186 | 225 | $49,980 | $15,506 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 92 | 104 | $33,275 | $10,031 | 30.1% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2022 | 11 | 12 | $29,520 | $8,071 | 27.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 48 | 49 | $22,870 | $7,716 | 33.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 35 | 35 | $28,175 | $6,605 | 23.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 64 | 65 | $62,400 | $6,441 | 10.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 65 | 67 | $47,235 | $6,440 | 13.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 33 | 33 | $15,690 | $4,052 | 25.8% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 21 | 21 | $16,905 | $3,956 | 23.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 39 | 50 | $9,225 | $2,890 | 31.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 32 | $7,407 | $2,636 | 35.6% |
About Dr. David Cohen, MD
Dr. David Cohen, MD is a Internal Medicine healthcare provider based in Attleboro, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649205790.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Cohen, MD has received a total of $6,316 in payments from pharmaceutical and medical device companies, with $1,868 received in 2024. These payments were reported across 314 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($6,316).
As a Medicare-enrolled provider, Cohen has provided services to 3,399 Medicare beneficiaries, totaling 3,819 services with total Medicare billing of $384,846. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Attleboro, MA
- Active Since 07/11/2006
- Last Updated 10/26/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1649205790
Products in Payments
- XIFAXAN (Drug) $697.53
- STELARA (Biological) $449.76
- Humira (Biological) $443.92
- RINVOQ (Biological) $327.73
- SUCRAID (Drug) $301.68
- SKYRIZI (Biological) $262.13
- DUPIXENT (Biological) $256.53
- VIBERZI (Drug) $205.51
- TRULANCE (Drug) $192.14
- OMVOH (Drug) $188.50
- ZEPOSIA (Drug) $184.54
- LINZESS (Drug) $158.18
- Cimzia (Drug) $152.17
- Sucraid (Drug) $132.96
- Creon (Drug) $130.64
- ENTYVIO (Biological) $128.54
- Linzess (Drug) $127.57
- CREON (Drug) $114.86
- XELJANZ (Drug) $114.60
- Entyvio (Biological) $104.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Attleboro
Sreekala Vasudevan, M.d, M.D
Internal Medicine — Payments: $21,120
Dr. Prabhu Ram, M.d, M.D
Internal Medicine — Payments: $9,012
Dr. Chadi Kaba, M.d, M.D
Internal Medicine — Payments: $2,583
Asma Latif, M.d, M.D
Internal Medicine — Payments: $2,460
Dr. Glenn Tucker, M.d, M.D
Internal Medicine — Payments: $1,943
Dr. Matthew Brumbaugh, M.d, M.D
Internal Medicine — Payments: $1,082